XL-188

• CAT Number: I038435
• CAS Number: 2305045-76-3
• Molecular Formula: C32H42N6O4
• Molecular Weight: 574.73
• Purity: 98%
• Synonyms: XL-188; XL 188; XL188
• Target: Deubiquitinase
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: N-[3-[[4-hydroxy-1-[(3R)-3-phenylbutanoyl]piperidin-4-yl]methyl]-4-oxoquinazolin-7-yl]-3-(4-methylpiperazin-1-yl)propanamide
• InChI: InChI=1S/C32H42N6O4/c1-24(25-6-4-3-5-7-25)20-30(40)37-14-11-32(42,12-15-37)22-38-23-33-28-21-26(8-9-27(28)31(38)41)34-29(39)10-13-36-18-16-35(2)17-19-36/h3-9,21,23-24,42H,10-20,22H2,1-2H3,(H,34,39)/t24-/m1/s1
• InChIKey: QLBYDWATOPNXBG-XMMPIXPASA-N
• SMILES: C[C@H](CC(=O)N1CCC(CC1)(CN2C=NC3=C(C2=O)C=CC(=C3)NC(=O)CCN4CCN(CC4)C)O)C5=CC=CC=C5

XL-188（Cat No.:I038435）is a selective inhibitor of heat shock protein 90 (HSP90), a molecular chaperone involved in the stabilization and activation of various proteins that regulate cell growth, survival, and stress response. By inhibiting HSP90, XL-188 disrupts the folding and function of several client proteins, including those involved in cancer cell proliferation and resistance to apoptosis. This makes XL-188 a promising candidate for cancer therapy, particularly for tumors that rely on HSP90-dependent proteins for survival. Preclinical studies have shown potential efficacy, and further clinical trials are ongoing to evaluate its safety and therapeutic potential.

Reference

Stolte B, Iniguez AB, Dharia NV, et al. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. J Exp Med. 2018;215(8):2137–2155. doi:10.1084/jem.20171066